Evidence map›Paper›PMID 27893708›Full record

ArticleOncogene2017

TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability.

W-T Liu, K-Y Huang, M-C Lu, H-L Huang, C-Y Chen, Y-L Cheng, H-C Yu, S-Q Liu, N-S Lai, H-B Huang

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Deubiquitylating Enzymes in Cancer and Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

W-T LiuDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
K-Y HuangDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
M-C LuSection of Allergy, Immunology and Rheumatology, Department of Medicine, DaLin Tzu-Chi Buddhist Hospital, Chia-Yi, Taiwan.
H-L HuangDepartment of Nutrition and Health Science, Fooyin University, Kaohsiung, Taiwan.
C-Y ChenDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
Y-L ChengDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
H-C YuDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
S-Q LiuSection of Allergy, Immunology and Rheumatology, Department of Medicine, DaLin Tzu-Chi Buddhist Hospital, Chia-Yi, Taiwan.
N-S LaiSection of Allergy, Immunology and Rheumatology, Department of Medicine, DaLin Tzu-Chi Buddhist Hospital, Chia-Yi, Taiwan.
H-B HuangDepartment of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan.
National Chung Cheng University · TWTzu Chi University · TWBuddhist Tzu Chi General Hospital · TWFooyin University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crosstalk between transforming growth factor beta (TGF-β) signaling and p53 has a critical role in cancer progression. TGF-β signals via Smad and non-Smad pathways. Under normal conditions, wild-type p53 forms a complex with Smad2/3 and co-activates transcription of a variety of tumor suppressor genes, resulting in tumor suppressive effects. Thus, p53 stability is essential in progression of tumor suppressive responses mediated by TGF-β signaling. However, it remains unknown whether p53 stability is regulated by TGF-β. In the current study, we identify that USP15 binds to and stabilizes p53 through deubiquitination in U2OS and HEK293 cells. TGF-β promotes the translation of USP15 through activation of mammalian target of rapamycin by the phosphoinositide 3-kinase/AKT pathway. Upregulation of USP15 translation links the crosstalk between TGF-β signaling and p53 stability, allowing this cytokine to have a critical role in cancer progression.

Indexed as

ApoptosisCell ProliferationGene Expression Regulation, NeoplasticHEK293 CellsHumansNeoplasmsPhosphatidylinositol 3-KinasesProtein BindingProtein StabilityProto-Oncogene Proteins c-aktSignal TransductionSmad2 ProteinTransforming Growth Factor betaTumor Suppressor Protein p53Ubiquitin-Specific ProteasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSmad2 ProteinSMAD2 protein, humanTP53 protein, humanTransforming Growth Factor betaTumor Suppressor Protein p53Ubiquitin-Specific ProteasesUSP15 protein, human

Identifiers

PMID27893708
PMCPMC5442427
OpenAlexW2558360196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.